Page 10«..9101112..2030..»

Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in…

Posted: January 27, 2025 at 2:49 am

FORT LEE, N.J., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a portfolio company of HLB Co., Ltd., today announced the results from a post-hoc analysis of the international CARES-310 study evaluating camrelizumab plus rivoceranib vs. sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC) of viral and non-viral etiology. The post-hoc analysis will be presented in a poster at the 2025 American Society of Clinical Oncology's annual Gastrointestinal Cancers Symposium (ASCO GI) on January 24.

Read more:
Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in...

Posted in Global News Feed | Comments Off on Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in…

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

Posted: January 27, 2025 at 2:49 am

PRESS RELEASE

More:
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

Posted in Global News Feed | Comments Off on AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Posted: January 27, 2025 at 2:49 am

Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

More:
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Posted in Global News Feed | Comments Off on Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated…

Posted: January 27, 2025 at 2:49 am

Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data

Read the original:
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated...

Posted in Global News Feed | Comments Off on Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated…

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Posted: January 27, 2025 at 2:49 am

WARREN, N.J., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers, announced today that it has broadened its relationship with Microsoft (Nasdaq: MSFT) to broaden its AI-focused collaboration and build its PredicTcell technology. PredicTcell is Tevogen Bio’s proprietary technology designed for predictive precision T cell targeting. This expanded relationship is designed to harness Microsoft’s cutting-edge AI, cloud capabilities, and Microsoft’s health and life sciences domain expertise to accelerate Tevogen Bio’s target identification and pre-clinical processes, strengthening the company’s pipeline of innovative immunotherapies.

Go here to read the rest:
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Posted in Global News Feed | Comments Off on Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Posted: January 27, 2025 at 2:49 am

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

See the original post here:
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Posted in Global News Feed | Comments Off on FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular…

Posted: January 27, 2025 at 2:49 am

Basel, 27 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys™ (delandistrogene moxeparvovec), the first approved gene therapy for the treatment of individuals with Duchenne muscular dystrophy. Two years after treatment with Elevidys, statistically significant and clinically meaningful improvements were observed across three key motor function measures of NSAA, TTR and 10MWR, when compared to a pre-specified propensity-weighted untreated external control group.* Functional differences between individuals treated with Elevidys and those in the external control group increased between one and two years after dosing. Together, these results demonstrate consistent, sustained benefit in favour of Elevidys.

Follow this link:
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular...

Posted in Global News Feed | Comments Off on Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular…

Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of…

Posted: January 27, 2025 at 2:49 am

Cambridge, UK, 27 January 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces it has appointed Dr Heather Preston as new Non-Executive Chair, and has secured further funding to progress its lead programme in Huntington’s Disease. This brings on board pharmaceutical investor Ono Ventures Investment, joined by existing investors, Takeda Ventures, SV Health Investors’ Dementia Discovery Fund and Epidarex Capital.

See the original post here:
Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of...

Posted in Global News Feed | Comments Off on Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of…

AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease

Posted: January 27, 2025 at 2:49 am

Lausanne (Switzerland), January 27, 2025 — AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic hyperinflammatory diseases and conditions driven by IL-18, announced today it has entered into an option and licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company with extensive experience in marketing rare disease therapeutics in the U.S.

Here is the original post:
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease

Posted in Global News Feed | Comments Off on AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease

Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation

Posted: January 27, 2025 at 2:49 am

Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourth quarter 2024 results, on Friday, January 31, 2025.

View original post here:
Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation

Posted in Global News Feed | Comments Off on Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation

Page 10«..9101112..2030..»